Quick Answer
Coherus Oncology, Inc. reported Cash And Cash Equivalents At Carrying Value of $88.88 million for the year ending 2025.
- Coherus Oncology, Inc. showed a decrease of -29.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $34.72 million | Q1 2014: $56.32 million | Q2 2014: $108.87 million | Q3 2014: $100.88 million | Q1 2015: $115.14 million | Q2 2015: $206.09 million | Q3 2015: $153.69 million | Q1 2016: $179.56 million | Q2 2016: $220.92 million | Q3 2016: $159.68 million | Q1 2017: $124.92 million | Q2 2017: $73.35 million | Q3 2017: $135.56 million | Q1 2018: $82.02 million | Q2 2018: $130.01 million | Q3 2018: $101.20 million | Q1 2019: $81.52 million | Q2 2019: $105.93 million | Q3 2019: $165.12 million | Q1 2020: $193.25 million | Q2 2020: $224.62 million | Q3 2020: $292.47 million | Q1 2021: $259.49 million | Q2 2021: $329.74 million | Q3 2021: $360.54 million | Q1 2022: $325.68 million | Q2 2022: $275.48 million | Q3 2022: $286.81 million | Q1 2023: $16.15 million | Q2 2023: $72.92 million | Q3 2023: $80.26 million | Q1 2024: $259.78 million | Q2 2024: $159.24 million | Q3 2024: $97.69 million | Q1 2025: $82.41 million | Q2 2025: $216.89 million | Q3 2025: $103.35 million.
- Over the full 15 years of available data (2011 to 2025), Coherus Oncology, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,056.7%.
- Historical annual values: Fiscal year 2025: $88.88 million | Fiscal year 2024: $125.99 million | Fiscal year 2023: $102.89 million | Fiscal year 2022: $63.55 million | Fiscal year 2021: $417.20 million | Fiscal year 2020: $541.16 million | Fiscal year 2019: $177.67 million | Fiscal year 2018: $72.36 million | Fiscal year 2017: $126.91 million | Fiscal year 2016: $124.95 million | Fiscal year 2015: $158.23 million | Fiscal year 2014: $150.39 million | Fiscal year 2013: $39.55 million | Fiscal year 2012: $14.55 million | Fiscal year 2011: $7.68 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: